Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens

Patent metadata

Field	Value
Publication number	US-12098173-B2
Application number	US-201917057418-A
Country	US
Kind code	B2
Filing date	May 22, 2019
Priority date	May 22, 2018
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

First claim

What is claimed is:

1. An isolated recombinant polypeptide comprising or consisting of: a β-solenoid structured polypeptide comprising amino acids from an innocuous β-solenoid scaffold polypeptide and a plurality of epitope amino acids from a disease associated polypeptide, wherein said plurality of epitope amino acids occur at every second residue in a β-strand of said β-solenoid structured polypeptide and comprise exposed side chains that project or are configured to project to an exterior position of a β-solenoid domain of the β-solenoid structured polypeptide.

2. The isolated recombinant polypeptide of claim 1 , wherein said β-solenoid structured polypeptide comprises one or more β-arcs comprising a plurality of said epitope amino acids from said disease associated polypeptide.

3. The isolated recombinant polypeptide of claim 1 , wherein said β-solenoid scaffold polypeptide comprises a β-solenoid sequence from Het-s, Het-2s, pectate lyase 3, Ca2+-dependent beta-helical antifreeze protein, high molecular weight (HMW) adhesin, Poly(beta-D-mannuronate) C5 epimerase 4, or endopolygalacturonase.

4. The isolated recombinant polypeptide of claim 2 , wherein said β-solenoid scaffold polypeptide comprises a polypeptide having a sequence as set forth in any one of SEQ ID NOs: 1, 11, 24, 26, 30, and 32.

5. The isolated recombinant polypeptide of claim 1 , wherein said disease associated polypeptide is scrapie prion protein (PrP Sc ), microtubule-associated protein tau, α-synuclein, prion protein (PrP), Aβ, or β-2-microglobulin.

6. The isolated recombinant polypeptide of claim 1 , wherein said β-solenoid domain polypeptide is left-handed.

7. The isolated recombinant polypeptide of claim 1 , wherein said β-solenoid domain polypeptide is right-handed.

8. The isolated recombinant polypeptide of claim 1 , wherein said β-solenoid domain polypeptide comprises a seven-rung, a four-rung or a two-rung β-solenoid domain.

9. The isolated recombinant polypeptide of claim 1 , comprising the amino acid sequence set forth in any one of SEQ ID NOs: 3, 19, 20, 21, 22, 25, 27, and 28.

10. A method of treating a subject having or suspected of having or at risk of developing a prion related disease or disorder, a neurodegenerative disease or disorder, or a proteinopathy, comprising administering an immunogenic composition comprising an isolated recombinant polypeptide according to claim 1 , a pharmaceutically acceptable excipient, and, optionally, an adjuvant.

11. The method of claim 10 , wherein said prion related disease or disorder, or said neurodegenerative disease or disorder, or said proteinopathy, is Alzheimer's disease (AD), Parkinson's disease (PD), Lewy Body Dementia (LBD), Multiple System Atrophy (MSA), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), Ataxia Telangiectasia Friedreich's Ataxia, Multiple Sclerosis (MS), Prion diseases, Spinocerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), Traumatic Brain Injury, spongiform encephalopathies (TSE), Creutzfeldt-Jakob disease (CJD), new variant CJD, Kuru, Gerstmann-StrAussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), dialysis-related amyloidosis (DRA) in humans, scrapie in sheep and goats, spongiform encephalopathy in cattle, or chronic wasting disease(CWD) in cervids.

12. The method of claim 10 , wherein said subject is a human or an animal.

13. The method of claim 10 , wherein the isolated recombinant polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 34.

14. The method of claim 10 , wherein the isolated recombinant polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 3, 19, 20, 21, 22, 25, 27, and 28.

Assignees

• Univ Alberta

Inventors

• Wille Holger
• Fang Jiarui
• Flores-Fernández José Miguel
• Rathod Vineet
• Tang Xinli

Classifications

• C12Y402/02002

  Pectate lyase (4.2.2.2) · CPC title

• C12N9/88

  Lyases (4.) · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K16/2872

  against prion molecules, e.g. CD230 · CPC title

• C07K16/18

  against material from animals or humans · CPC title